Currently, LENZ Therapeutics Inc [LENZ] is trading at $41.85, up 7.86%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LENZ shares have lost -13.89% over the last week, with a monthly amount glided 1.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen started tracking the stock with Buy rating on March 18, 2025, and set its price target to $60. On September 27, 2024, Raymond James initiated with a Outperform rating and assigned a price target of $37 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $38 on August 12, 2024. William Blair initiated its recommendation with a Outperform. Leerink Partners started tracking with a Outperform rating for this stock on April 15, 2024, and assigned it a price target of $32. In a note dated April 10, 2024, Citigroup initiated a Buy rating and provided a target price of $34 on this stock.
This stock has fluctuated between a low of $16.53 and a high of $50.40 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $67 within the next 12 months. LENZ Therapeutics Inc [NASDAQ: LENZ] shares were valued at $41.85 at the most recent close of the market. An investor can expect a potential return of 60.1% based on the average LENZ price forecast.
Analyzing the LENZ fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -12.23%, Pretax Profit Margin comes in at -10.24%, and Net Profit Margin reading is -10.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.26 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for LENZ Therapeutics Inc [NASDAQ:LENZ] is 20.54. Also, the Quick Ratio is 20.54, while the Cash Ratio stands at 3.62. Considering the valuation of this stock, the price to sales ratio is 238.73, the price to book ratio is 5.78.
Transactions by insiders
Recent insider trading involved Versant Venture Capital VI, L., 10% Owner, that happened on Sep 30 ’25 when 0.13 million shares were sold. 10% Owner, Versant Venture Capital VI, L. completed a deal on Sep 30 ’25 to sell 92030.0 shares. Meanwhile, 10% Owner Versant Venture Capital VI, L. sold 90654.0 shares on Sep 18 ’25.
